Belinda K Cornes1,2, Jennifer A Brody3, Naghmeh Nikpoor4, Alanna C Morrison5, Huan Chu4, Byung Soo Ahn4, Shuai Wang6, Marco Dauriz1,2,7, Joshua I Barzilay8, Josée Dupuis6,9, Jose C Florez2,10,11, Josef Coresh12,13, Richard A Gibbs14, W H Linda Kao13, Ching-Ti Liu6, Barbara McKnight3,15, Donna Muzny14, James S Pankow16, Jeffrey G Reid13, Charles C White6, Andrew D Johnson9, Tien Y Wong17,18, Bruce M Psaty19, Eric Boerwinkle5,14, Jerome I Rotter20, David S Siscovick3,21, Robert Sladek4, James B Meigs1,2. 1. General Medicine Division, Massachusetts General Hospital, Boston, Massachusetts, USA. 2. Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. 3. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA. 4. Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. 5. Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA. 6. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 7. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona Medical School and Hospital Trust of Verona, Verona, Italy. 8. Division of Endocrinology, Kaiser Permanente of Georgia and Emory University School of Medicine. 9. National Heart, Lung, and Blood Institute's The Framingham Heart Study, Cardiovascular Epidemiology and Human Genomics Center, Framingham, MA, USA. 10. Center for Human Genetic Research, Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. 11. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. 12. Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. 13. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA. 14. Human Genome Sequencing Center, Baylor College of Medicine, University of Texas Health Science Center, Houston, TX. 15. Department of Biostatistics, University of Washington, Seattle, WA, USA. 16. Division of Epidemiology and Community Health (J.S.P.), University of Minnesota, MN, USA. 17. Singapore Eye Research Institute, Singapore National Eye Centre, Duke-NUS Graduate Medical School, Singapore. 18. Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 19. Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, WA; Group Health Research Institute, Group Health Cooperative, Seattle, WA. 20. Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Reasearch Institute and Department of Pediatrics, Harbor-UCLA Medical Center Torrance, California, USA. 21. Cardiovascular Health Research Unit, Department of Epidemiology, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Common variation at the 11p11.2 locus, encompassing MADD, ACP2, NR1H3, MYBPC3, and SPI1, has been associated in genome-wide association studies with fasting glucose and insulin (FI). In the Cohorts for Heart and Aging Research in Genomic Epidemiology Targeted Sequencing Study, we sequenced 5 gene regions at 11p11.2 to identify rare, potentially functional variants influencing fasting glucose or FI levels. METHODS AND RESULTS: Sequencing (mean depth, 38×) across 16.1 kb in 3566 individuals without diabetes mellitus identified 653 variants, 79.9% of which were rare (minor allele frequency <1%) and novel. We analyzed rare variants in 5 gene regions with FI or fasting glucose using the sequence kernel association test. At NR1H3, 53 rare variants were jointly associated with FI (P=2.73×10(-3)); of these, 7 were predicted to have regulatory function and showed association with FI (P=1.28×10(-3)). Conditioning on 2 previously associated variants at MADD (rs7944584, rs10838687) did not attenuate this association, suggesting that there are >2 independent signals at 11p11.2. One predicted regulatory variant, chr11:47227430 (hg18; minor allele frequency=0.00068), contributed 20.6% to the overall sequence kernel association test score at NR1H3, lies in intron 2 of NR1H3, and is a predicted binding site for forkhead box A1 (FOXA1), a transcription factor associated with insulin regulation. In human HepG2 hepatoma cells, the rare chr11:47227430 A allele disrupted FOXA1 binding and reduced FOXA1-dependent transcriptional activity. CONCLUSIONS: Sequencing at 11p11.2-NR1H3 identified rare variation associated with FI. One variant, chr11:47227430, seems to be functional, with the rare A allele reducing transcription factor FOXA1 binding and FOXA1-dependent transcriptional activity.
BACKGROUND: Common variation at the 11p11.2 locus, encompassing MADD, ACP2, NR1H3, MYBPC3, and SPI1, has been associated in genome-wide association studies with fasting glucose and insulin (FI). In the Cohorts for Heart and Aging Research in Genomic Epidemiology Targeted Sequencing Study, we sequenced 5 gene regions at 11p11.2 to identify rare, potentially functional variants influencing fasting glucose or FI levels. METHODS AND RESULTS: Sequencing (mean depth, 38×) across 16.1 kb in 3566 individuals without diabetes mellitus identified 653 variants, 79.9% of which were rare (minor allele frequency <1%) and novel. We analyzed rare variants in 5 gene regions with FI or fasting glucose using the sequence kernel association test. At NR1H3, 53 rare variants were jointly associated with FI (P=2.73×10(-3)); of these, 7 were predicted to have regulatory function and showed association with FI (P=1.28×10(-3)). Conditioning on 2 previously associated variants at MADD (rs7944584, rs10838687) did not attenuate this association, suggesting that there are >2 independent signals at 11p11.2. One predicted regulatory variant, chr11:47227430 (hg18; minor allele frequency=0.00068), contributed 20.6% to the overall sequence kernel association test score at NR1H3, lies in intron 2 of NR1H3, and is a predicted binding site for forkhead box A1 (FOXA1), a transcription factor associated with insulin regulation. In humanHepG2hepatoma cells, the rare chr11:47227430 A allele disrupted FOXA1 binding and reduced FOXA1-dependent transcriptional activity. CONCLUSIONS: Sequencing at 11p11.2-NR1H3 identified rare variation associated with FI. One variant, chr11:47227430, seems to be functional, with the rare A allele reducing transcription factor FOXA1 binding and FOXA1-dependent transcriptional activity.
Authors: Nan Gao; John Le Lay; Wei Qin; Nicolai Doliba; Jonathan Schug; Alan J Fox; Olga Smirnova; Franz M Matschinsky; Klaus H Kaestner Journal: Mol Endocrinol Date: 2010-06-09
Authors: Michael P Verzi; Hyunjin Shin; H Hansen He; Rita Sulahian; Clifford A Meyer; Robert K Montgomery; James C Fleet; Myles Brown; X Shirley Liu; Ramesh A Shivdasani Journal: Dev Cell Date: 2010-11-16 Impact factor: 12.270
Authors: Noa Novershtern; Aravind Subramanian; Lee N Lawton; Raymond H Mak; W Nicholas Haining; Marie E McConkey; Naomi Habib; Nir Yosef; Cindy Y Chang; Tal Shay; Garrett M Frampton; Adam C B Drake; Ilya Leskov; Bjorn Nilsson; Fred Preffer; David Dombkowski; John W Evans; Ted Liefeld; John S Smutko; Jianzhu Chen; Nir Friedman; Richard A Young; Todd R Golub; Aviv Regev; Benjamin L Ebert Journal: Cell Date: 2011-01-21 Impact factor: 41.582
Authors: Gonçalo R Abecasis; David Altshuler; Adam Auton; Lisa D Brooks; Richard M Durbin; Richard A Gibbs; Matt E Hurles; Gil A McVean Journal: Nature Date: 2010-10-28 Impact factor: 49.962
Authors: Tanja Zeller; Philipp Wild; Silke Szymczak; Maxime Rotival; Arne Schillert; Raphaele Castagne; Seraya Maouche; Marine Germain; Karl Lackner; Heidi Rossmann; Medea Eleftheriadis; Christoph R Sinning; Renate B Schnabel; Edith Lubos; Detlev Mennerich; Werner Rust; Claire Perret; Carole Proust; Viviane Nicaud; Joseph Loscalzo; Norbert Hübner; David Tregouet; Thomas Münzel; Andreas Ziegler; Laurence Tiret; Stefan Blankenberg; François Cambien Journal: PLoS One Date: 2010-05-18 Impact factor: 3.240
Authors: J Raphael Gibbs; Marcel P van der Brug; Dena G Hernandez; Bryan J Traynor; Michael A Nalls; Shiao-Lin Lai; Sampath Arepalli; Allissa Dillman; Ian P Rafferty; Juan Troncoso; Robert Johnson; H Ronald Zielke; Luigi Ferrucci; Dan L Longo; Mark R Cookson; Andrew B Singleton Journal: PLoS Genet Date: 2010-05-13 Impact factor: 5.917
Authors: Gong-Hong Wei; Gwenael Badis; Michael F Berger; Teemu Kivioja; Kimmo Palin; Martin Enge; Martin Bonke; Arttu Jolma; Markku Varjosalo; Andrew R Gehrke; Jian Yan; Shaheynoor Talukder; Mikko Turunen; Mikko Taipale; Hendrik G Stunnenberg; Esko Ukkonen; Timothy R Hughes; Martha L Bulyk; Jussi Taipale Journal: EMBO J Date: 2010-06-01 Impact factor: 11.598
Authors: Kadri Haljas; Azmeraw T Amare; Behrooz Z Alizadeh; Yi-Hsiang Hsu; Thomas Mosley; Anne Newman; Joanne Murabito; Henning Tiemeier; Toshiko Tanaka; Cornelia van Duijn; Jingzhong Ding; David J Llewellyn; David A Bennett; Antonio Terracciano; Lenore Launer; Karl-Heinz Ladwig; Marylin C Cornelis; Alexander Teumer; Hans Grabe; Sharon L R Kardia; Erin B Ware; Jennifer A Smith; Harold Snieder; Johan G Eriksson; Leif Groop; Katri Räikkönen; Jari Lahti Journal: Psychosom Med Date: 2018-04 Impact factor: 4.312
Authors: Charumathi Sabanayagam; Weng Kit Lye; Ronald Klein; Barbara E K Klein; Mary Frances Cotch; Jie Jin Wang; Paul Mitchell; Jonathan E Shaw; Elizabeth Selvin; A Richey Sharrett; Tien Y Wong Journal: Diabetologia Date: 2015-08-02 Impact factor: 10.122
Authors: Christopher P Jenkinson; Harald H H Göring; Rector Arya; John Blangero; Ravindranath Duggirala; Ralph A DeFronzo Journal: Genom Data Date: 2015-12-17